Medivation Achieves Positive Outcomes From Study for Huntington’s Disease

Medivation saw promising data for its Phase II trial studying its investigational drug Dimebon for patients with mild-to-moderate Huntington’s disease.

Patients experienced improved cognitive functions with the drug as compared with placebo. The drug was well tolerated, Medivation said.

As part of a collaboration with the Huntington Study Group, the randomized, double-blind, placebo-controlled trial was conducted at 16 centers in the U.S. and the UK.